Alivus Life Sciences Limited

Alivus Life Sciences to hold Investor/Analyst Meeting on December 18, 2025

Alivus Life Sciences Limited will hold a virtual one-on-one meeting with investors and analysts on December 18, 2025. The schedule is subject to change.

Alivus Life Sciences to Meet Investors/Analysts December 16-18

Alivus Life Sciences Limited will hold one-on-one meetings with investors and analysts from December 16-18, 2025. Meetings are scheduled with Unique PMS, Yes Securities, JM Financial, Systematix, and SIMPL. The format includes both in-person and virtual interactions.

Intimation of Investor/Analyst Meet

Alivus Life Sciences Limited announced an in-person investor/analyst meeting with Quantum AMC on December 9, 2025, in Mumbai. The schedule is subject to change.

Alivus Life Sciences Limited - Intimation of Investor/Analyst Meetings

Alivus Life Sciences Limited announced upcoming investor/analyst meetings, including a virtual meeting with Kosh Wealth Management on December 4, 2025, and an in-person meeting with Karma Capital on December 5, 2025, in Mumbai.

Alivus Life Sciences Intimates Investor/Analyst Meet

Alivus Life Sciences Limited announced upcoming meetings with investors/analysts on December 2 and 3, 2025 in Mumbai.

Alivus Life Sciences Limited Announces Investor/Analyst Meetings

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced upcoming meetings with investors and analysts on November 19 and November 24, 2025.

Alivus Life Sciences Q2 FY26 Earnings Call Transcript

Alivus Life Sciences announced the transcript of its Q2 FY26 earnings call, reporting ₹588 crore revenue with 16% YoY growth. The company reaffirmed its guidance for FY26 with strong performance expected in the second half.

Alivus Life Sciences Uploads Audio Recording of Q2 FY2026 Earnings Call

Alivus Life Sciences Limited uploaded the audio recording of its Q2 FY2026 earnings call held on November 7, 2025, on its website.

Alivus Life Sciences Investor Presentation for Q2 FY26

Alivus Life Sciences announced its investor presentation for Q2 FY26, reporting revenue of ₹5,880 million, a growth of 16% YoY. EBITDA stood at ₹1,939 million with a margin of 33%.

Alivus Life Sciences reports 16% YoY revenue growth and 35.7% YoY EBITDA growth in Q2FY26

Alivus Life Sciences announced strong Q2FY26 results with 16% revenue growth and 35.7% EBITDA growth, driven by non-GPL business and positive outlook for H2.

Alivus Life Sciences Reports Strong Q2 and H1 FY26 Unaudited Financial Results

Alivus Life Sciences reported significant growth in Q2 and H1 FY26, with revenue and profit rising substantially. The Board approved the unaudited financial results for the period ended September 30, 2025.

Alivus Life Sciences Schedules Q2 FY2025-26 Earnings Call on November 7, 2025

Alivus Life Sciences Limited has scheduled an earnings call on November 7, 2025, to discuss its financial performance for the second quarter of FY2025-26.

Alivus Board to meet on Nov 6 to approve Q2FY26 unaudited financial results

Alivus will hold a board meeting on November 6, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025. The trading window is closed from September 30 to November 8, 2025.

Alivus Life Sciences fined ₹50 lakh by GPCB for Ankleshwar plant flash fire

Alivus Life Sciences received an order from GPCB imposing an interim Environment Damage Compensation of ₹50 lakh and requiring a ₹29 lakh deposit due to a flash fire incident at its Ankleshwar plant. The company states no material impact and may appeal.

Alivus Life Sciences receives ₹1.28 crore GST demand and ₹1.29 crore penalty order

Alivus Life Sciences' Bank Loan Facilities Upgraded to 'IND AA' by India Ratings; Outlook Stable

Alivus Life Sciences: Outcome of 14th AGM held on September 08, 2025

Alivus Life Sciences Announces Change in Corporate Office Address

Alivus Life Sciences to meet with Sowilo Investment Managers

Alivus Life Sciences to hold meetings with investors/analysts

Alivus Life Sciences receives Customs penalty of over ₹3.21 crore for alleged mis-classification

Alivus Life Sciences announces 14th AGM on September 8, 2025; sets record date

Alivus Life Sciences Uploads Audio Recording of Q1 FY26 Earnings Call

Alivus Life Sciences Q1 FY26 Revenue ₹6,018 Million, Non-GPL Business Up 14.5% YoY

Alivus Life Sciences Announces Unaudited Financial Results for Q1 Ended June 30, 2025

USFDA issues NAI classification after inspecting Alivus Life Sciences' Gujarat facility

Alivus Life Sciences Shareholders Approve Re-appointment of Independent Directors Via Postal Ballot

Alivus Life Sciences to Host Q1 FY2025-26 Earnings Call on August 2, 2025

Alivus Life Sciences to Convene Board Meeting on August 1 for Q1 FY26 Results